Download PDF
Thromb Haemost 2011; 106(06): 995-996
DOI: 10.1160/TH11-09-0655
Invited Editorial Focus
Schattauer GmbH

Should we focus on “venous vulnerability” instead of “plaque vulnerability” in symptomatic atherosclerotic patients?

Fabrizio Montecucco
1   Division of Cardiology, Foundation for Medical Researches, Department of Medical Specialties, University of Geneva, Geneva, Switzerland
,
François Mach
1   Division of Cardiology, Foundation for Medical Researches, Department of Medical Specialties, University of Geneva, Geneva, Switzerland
› Author Affiliations Financial support: This research was funded by EU FP7, Grant number 201668, AtheroRemo to Dr. F. Mach. This work was also supported by the Swiss National Science Foundation Grants to Dr. F. Mach (#310030–118245), Dr. Montecucco (#32002B-134963/1). This work was also funded by a grant from the Swiss Heart Foundation to Dr. F. Mach. This work was funded by the “Sir Jules Thorn Trust Reg” fund and Gustave and Simone Prévot fund to Dr. F. Montecucco.
Further Information

Publication History

Received: 19 September 2011

Accepted: 20 September 2011

Publication Date:
27 November 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3: e442
    CrossrefPubMedGoogle Scholar
  • 2 Naghavi M, Libby P, Falk E. et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation 2003; 108: 1664-1672.
    CrossrefPubMedGoogle Scholar
  • 3 Montecucco F, Vuilleumier N, Pagano S. et al. Anti-Apolipoprotein A-1 auto-antibodies are active mediators of atherosclerotic plaque vulnerability. Eur Heart J 2011; 32: 412-421.
    CrossrefPubMedGoogle Scholar
  • 4 Ridker PM, Danielson E, Fonseca FA. et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-2207.
    CrossrefPubMedGoogle Scholar
  • 5 Mirabelli-Badenier M, Braunersreuther V, Viviani GL. et al. CC and CXC chemokines are pivotal mediators of cerebral injury in ischaemic stroke. Thromb Haemost 2011; 105: 409-420.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 2011; 473: 317-325.
    CrossrefPubMedGoogle Scholar
  • 7 Sørensen HT, Horvath-Puho E, Pedersen L. et al. Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. Lancet 2007; 370: 1773-1779.
    CrossrefPubMedGoogle Scholar
  • 8 Prandoni P, Bilora F, Marchiori A. et al. An association between atherosclerosis and venous thrombosis. N Engl J Med 2003; 348: 1435-1441.
    CrossrefPubMedGoogle Scholar
  • 9 Brouwer JL, Lijfering WM, Ten Kate MK. et al. High long-term absolute risk of recurrent venous thromboembolism in patients with hereditary deficiencies of protein S, protein C or antithrombin. Thromb Haemost 2009; 101: 93-99.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Lijfering WM, Coppens M, van de Poel MH. et al. The risk of venous and arterial thrombosis in hyperhomocysteinaemia is low and mainly depends on concomitant thrombophilic defects. Thromb Haemost 2007; 98: 457-463.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Piazza G, Goldhaber S, Lessard D. et al. Venous Thromboembolism in patients with symptomatic atherosclerosis. Thromb Haemost 2011; 106: 1095-1102.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Alessi MC, Juhan-Vague I. Metabolic syndrome, haemostasis and thrombosis. Thromb Haemost 2008; 99: 995-1000.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Gresele P, Momi S, Migliacci R. Endothelium, venous thromboembolism and ischaemic cardiovascular events. Thromb Haemost 2010; 103: 56-61.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Geerts WH, Bergqvist D, Pineo GF. et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 381S-453S.
    CrossrefPubMedGoogle Scholar
  • 15 Ahrens I, Lip GY, Peter K. New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost 2010; 104: 49-60.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Khemasuwan D, Chae YK, Gupta S. et al. Dose-related Effect of Statins in Venous Thrombosis Risk Reduction. Am J Med 2011; 124: 852-859.
    CrossrefPubMedGoogle Scholar